National Research corporate does surveys for healthcare-related organizations. The operating business has grown around 14%/year over the last decade. Its CEO is obviously a Warren Buffett fan and (in my opinion) has higher integrity than Buffett.
Recently, National Research has performed a recapitalization that has created an A and B share structure. There is some uncertainty as to the relative economic interest between the two share classes. The B shares should be worth anywhere from 6X to 1X that of the A shares if voting rights and illiquidity are ignored. This is a huge range. Because of the uncertainty over the relative value of the two share classes, there are two different possible trades:
- Arbitrage. Go long the B shares and short the A shares. One could make the argument that the B shares have 6 times the economic interest of the A shares. On top of that, the B shares have higher voting power so they should trade at a slightly premium (though in practice it could trade at a discount due to illiquidity).
- Go long the B shares. National Research is a well-managed company run by a CEO with unusual integrity.
*Disclosure: Long NRCIB, no position in NRCIA.